Practical aspects of treatment with ocrelizumab – own experience Original article
Article Sidebar
Main Article Content
Abstract
Ocrelizumab (OCR) is a novel intravenous treatment approved in the EU and the USA for relapsing-forms of MS (RRMS) and, as a first medicine, also for the treatment of primary progressive multiple sclerosis (PPMS). OCR is an anti-CD20 monoclonal antibody that leads to selective depletion of CD20+ B cells. The author presents Danish recommendations and guidelines for OCR treatment. He also presents experience from the treatment of the first 22 patients, 21 with RRMS and 1 with PPMS, treated in his own center since October 2018. The author discusses problems regarding the selection of patients for OCR treatment, initiation of treatment, drug infusion and preliminary experience with tolerance, side effects and effectiveness of the drug in real life conditions.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. NEJM 2017; 376(3): 221-234.
3. Montalban X, Hauser SL, Kappos L et al. Ocrelizumab versus placebo in Primary Progressive Multiple Sclerosis. NEJM 2017; 376(3): 209-220.
4. Mayer L, Kappos L, Racke MK et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis. Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord 2019; 30: 236-243.
5. Liver Tox: Clinical and Research Information on Drug-Induced Liver Injury. Last update July 15, 2018.
6. Klotz L, Havla J, Schwab N et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 2019; 12: 1-31.
7. Barkhof F, Kappos L, Wolinsky JS et al. Onset of clinical and MRC efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology 2019; 93: 1778-1786.